NFJ Investment Group LLC Takes Position in BioMarin Pharmaceutical Inc. $BMRN

NFJ Investment Group LLC purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 67,991 shares of the biotechnology company’s stock, valued at approximately $3,890,000.

A number of other hedge funds have also bought and sold shares of BMRN. Rice Hall James & Associates LLC bought a new stake in shares of BioMarin Pharmaceutical in the second quarter valued at approximately $14,203,000. Swedbank AB grew its position in BioMarin Pharmaceutical by 70.6% during the fourth quarter. Swedbank AB now owns 796,737 shares of the biotechnology company’s stock worth $47,350,000 after buying an additional 329,794 shares in the last quarter. LSV Asset Management increased its stake in BioMarin Pharmaceutical by 4.3% during the 4th quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company’s stock worth $52,429,000 after acquiring an additional 36,700 shares during the period. GSA Capital Partners LLP bought a new position in BioMarin Pharmaceutical during the 2nd quarter worth $944,000. Finally, C WorldWide Group Holding A S increased its stake in BioMarin Pharmaceutical by 12.6% during the 4th quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company’s stock worth $15,918,000 after acquiring an additional 30,000 shares during the period. 98.71% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on BMRN. Royal Bank Of Canada cut their target price on BioMarin Pharmaceutical from $66.00 to $62.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. The Goldman Sachs Group began coverage on BioMarin Pharmaceutical in a research report on Monday, May 11th. They issued a “neutral” rating and a $69.00 price target on the stock. Barclays boosted their price target on BioMarin Pharmaceutical from $105.00 to $111.00 and gave the company an “overweight” rating in a research note on Monday. Canaccord Genuity Group upped their price objective on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Finally, Piper Sandler increased their price objective on shares of BioMarin Pharmaceutical from $82.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $88.83.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $67.68 on Friday. The company has a 50 day simple moving average of $60.45 and a 200 day simple moving average of $57.82. The stock has a market cap of $13.10 billion, a price-to-earnings ratio of 182.92, a P/E/G ratio of 0.50 and a beta of 0.24. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.25. The firm had revenue of $989.71 million for the quarter, compared to analyst estimates of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company’s quarterly revenue was up 20.0% on a year-over-year basis. During the same quarter last year, the business posted $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.11 EPS for the current fiscal year.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BMO upgrades BioMarin to “strong buy.” The upgrade follows BMO’s recent initiation of coverage with an “outperform” rating and a $98 price target, implying substantial upside from the current trading level. BMO upgrades BioMarin to strong buy
• Positive Sentiment: Alesta acquisition expands BioMarin’s rare-disease pipeline. BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The deal adds ALE1, an oral treatment candidate for hypophosphatasia, a rare genetic bone disorder, and could strengthen the company’s long-term growth prospects if development and regulatory milestones are achieved. BioMarin Alesta acquisition
• Positive Sentiment: Recent operating results were stronger than expected. BioMarin’s latest reported quarter exceeded consensus earnings and revenue estimates, with revenue increasing 20% year over year. Articles from Barclays and Piper Sandler also point to potential share-price appreciation. BioMarin Q2 results benchmarking
• Neutral Sentiment: The Alesta opportunity remains early stage. ALE1 is still in clinical development, meaning the potential commercial benefit is several years away and depends on successful trials, approvals and milestone execution. The transaction therefore adds strategic potential but also development risk. BioMarin to acquire Alesta
• Negative Sentiment: Analyst opinion is not unanimous. HC Wainwright issued a pessimistic forecast, while another analyst reduced the price target to $59 despite viewing the Alesta deal favorably. This valuation disagreement may limit near-term upside and contribute to selling pressure. BioMarin analyst price target cut

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.